Endothelial dysfunction in chronic inflammatory diseases

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 11324-11349

  Steyers III, Curtis M ^a   Miller Jr , Francis J ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Arthritis; Atherosclerosis; Endothelial dysfunction; Endothelium; Inflammation; Inflammatory disease

Indexed keywords

ANTIINFLAMMATORY AGENT; AUTOANTIBODY; BIOLOGICAL MARKER; CORTICOSTEROID; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; METHOTREXATE; N (G), N (G) DIMETHYLARGININE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL MEMBRANE PERMEABILITY; CHRONIC ARTHRITIS; COLLAGEN-INDUCED ARTHRITIS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FLOW MEDIATED VASODILATION; FOREARM BLOOD FLOW; HUMAN; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; LEUKOCYTE ADHERENCE; MICROVASCULAR VASODILATION; OXIDATIVE STRESS; PROGNOSIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; VASODILATATION; ANIMAL; ARTHRITIS; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ARTHRITIS; ATHEROSCLEROSIS; CHOLESTEROL, LDL; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903397422     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150711324     Document Type: Review

References (139)

1. Murdaca, G.; Colombo, B. M.; Cagnati, P.; Gulli, R.; Spano, F.; Puppo, F. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012, 224, 309-317.
2. Prati, C.; Demougeot, C.; Guillot, X.; Godfrin-Valnet, M.; Wendling, D. Endothelial dysfunction in joint disease. Jt. Bone Spine 2014, doi: 10. 1016/j. jbspin. 2014. 01. 014.
3. Nikpour, M.; Gladman, D. D.; Urowitz, M. B. Premature coronary heart disease in systemic lupus erythematosus: What risk factors do we understand? Lupus 2013, 22, 1243-1250.
4. Peters, M. J.; van der Horst-Bruinsma, I. E.; Dijkmans, B. A.; Nurmohamed, M. T. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin. Arthritis Rheum. 2004, 34, 585-592.
5. Mathieu, S.; Motreff, P.; Soubrier, M. Spondyloarthropathies: an independent cardiovascular risk factor? Jt. Bone Spine 2010, 77, 542-545.
6. Singh, S.; Singh, H.; Loftus, E. V., Jr.; Pardi, D. S. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2014, 12, 382-393 e381.
7. Gelfand, J. M.; Neimann, A. L.; Shin, D. B.; Wang, X.; Margolis, D. J.; Troxel, A. B. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296, 1735-1741.
8. Rosner, S.; Ginzler, E. M.; Diamond, H. S.; Weiner, M.; Schlesinger, M.; Fries, J. F.; Wasner, C.; Medsger, T. A., Jr.; Ziegler, G.; Klippel, J. H.; et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum. 1982, 25, 612-617.
9. Davignon, J.; Ganz, P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109, III27-III32.
10. Bonetti, P. O. Endothelial Dysfunction: A Marker of Atherosclerotic Risk. Arterioscler Thromb Vasc Biol 2002, 23, 168-175.
11. Ross, R. Atherosclerosis--an inflammatory disease. N. Engl. J. Med. 1999, 340, 115-126.
12. Lind, L.; Hall, J.; Larsson, A.; Annuk, M.; Fellstrom, B.; Lithell, H. Evaluation of endothelium-dependent vasodilation in the human peripheral circulation. Clin. Physiol. 2000, 20, 440-448.
13. Deanfield, J. E.; Halcox, J. P.; Rabelink, T. J. Endothelial function and dysfunction: Testing and clinical relevance. Circulation 2007, 115, 1285-1295.
14. Ghiadoni, L.; Salvetti, M.; Muiesan, M. L.; Taddei, S. Evaluation of endothelial function by flow mediated dilation: Methodological issues and clinical importance. High Blood Press Cardiovasc. Prev. 2014, in press.
15. Anderson, T. J.; Uehata, A.; Gerhard, M. D.; Meredith, I. T.; Knab, S.; Delagrange, D.; Lieberman, E. H.; Ganz, P.; Creager, M. A.; Yeung, A. C.; et al. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 1995, 26, 1235-1241.
16. Widlansky, M. E.; Gokce, N.; Keaney, J. F.; Vita, J. A. The clinical implications of endothelial dysfunction. J. Am. Coll. Cardiol. 2003, 42, 1149-1160.
17. Inaba, Y.; Chen, J. A.; Bergmann, S. R. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: A meta-analysis. Int. J. Cardiovasc. Imaging 2010, 26, 631-640.
18. Roustit, M.; Cracowski, J. L. Non-invasive assessment of skin microvascular function in humans: An insight into methods. Microcirculation 2012, 19, 47-64.
19. Recio-Mayoral, A.; Mason, J. C.; Kaski, J. C.; Rubens, M. B.; Harari, O. A.; Camici, P. G. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur. Heart J. 2009, 30, 1837-1843.
20. Ridker, P. M.; Hennekens, C. H.; Roitman-Johnson, B.; Stampfer, M. J.; Allen, J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998, 351, 88-92.
21. Hwang, S. J.; Ballantyne, C. M.; Sharrett, A. R.; Smith, L. C.; Davis, C. E.; Gotto, A. M., Jr.; Boerwinkle, E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997, 96, 4219-4225.
22. Sibal, L.; Agarwal, S. C.; Home, P. D.; Boger, R. H. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr. Cardiol. Rev. 2010, 6, 82-90.
23. Boger, R. H.; Maas, R.; Schulze, F.; Schwedhelm, E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. Pharmacol. Res. 2009, 60, 481-487.
24. Hill, J. M.; Zalos, G.; Halcox, J. P.; Schenke, W. H.; Waclawiw, M. A.; Quyyumi, A. A.; Finkel, T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 2003, 348, 593-600.
25. Samarasekera, E. J.; Neilson, J. M.; Warren, R. B.; Parnham, J.; Smith, C. H. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J. Investig. Dermatol. 2013, 133, 2340-2346.
26. Crowson, C. S.; Liao, K. P.; Davis, J. M., 3rd; Solomon, D. H.; Matteson, E. L.; Knutson, K. L.; Hlatky, M. A.; Gabriel, S. E. Rheumatoid arthritis and cardiovascular disease. Am. Heart J. 2013, 166, 622-628 e621.
27. Solomon, D. H.; Goodson, N. J.; Katz, J. N.; Weinblatt, M. E.; Avorn, J.; Setoguchi, S.; Canning, C.; Schneeweiss, S. Patterns of cardiovascular risk in rheumatoid arthritis. Ann. Rheum. Dis. 2006, 65, 1608-1612.
28. Avina-Zubieta, J. A.; Choi, H. K.; Sadatsafavi, M.; Etminan, M.; Esdaile, J. M.; Lacaille, D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Rheum. 2008, 59, 1690-1697.
29. Hak, A. E.; Karlson, E. W.; Feskanich, D.; Stampfer, M. J.; Costenbader, K. H. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum. 2009, 61, 1396-1402.
30. Magder, L. S.; Petri, M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am. J. Epidemiol. 2012, 176, 708-719.
31. Bernatsky, S.; Boivin, J. F.; Joseph, L.; Manzi, S.; Ginzler, E.; Gladman, D. D.; Urowitz, M.; Fortin, P. R.; Petri, M.; Barr, S.; et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006, 54, 2550-2557.
32. Mathieu, S.; Gossec, L.; Dougados, M.; Soubrier, M. Cardiovascular profile in ankylosing spondylitis: A systematic review and meta-analysis. Arthritis Care Res. (Hoboken) 2011, 63, 557-563.
33. Peters, M. J.; Visman, I.; Nielen, M. M.; van Dillen, N.; Verheij, R. A.; van der Horst-Bruinsma, I. E.; Dijkmans, B. A.; Nurmohamed, M. T. Ankylosing spondylitis: A risk factor for myocardial infarction? Ann. Rheum. Dis. 2010, 69, 579-581.
34. Fumery, M.; Xiaocang, C.; Dauchet, L.; Gower-Rousseau, C.; Peyrin-Biroulet, L.; Colombel, J. F. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies. J. Crohns Colitis 2014, 8, 469-479.
35. Dorn, S. D.; Sandler, R. S. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: Results from a systematic review and meta-analysis. Am. J. Gastroenterol. 2007, 102, 662-667.
36. Bergholm, R. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1637-1641.
37. Chatterjee Adhikari, M.; Guin, A.; Chakraborty, S.; Sinhamahapatra, P.; Ghosh, A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: An observational study. Semin. Arthritis Rheum. 2012, 41, 669-675.
38. Kerekes, G.; Szekanecz, Z.; Der, H.; Sandor, Z.; Lakos, G.; Muszbek, L.; Csipo, I.; Sipka, S.; Seres, I.; Paragh, G.; et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: A multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 2008, 35, 398-406.
39. Vaudo, G. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann. Rheum. Dis. 2004, 63, 31-35.
40. Hänsel, S.; Lässig, G.; Pistrosch, F.; Passauer, J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003, 170, 177-180.
41. Syngle, A.; Vohra, K.; Kaur, L.; Sharma, S. Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis. Scand. J. Rheumatol. 2009, 38, 15-22.
42. Datta, D.; Ferrell, W. R.; Sturrock, R. D.; Jadhav, S. T.; Sattar, N. Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 2007, 192, 391-395.
43. Galarraga, B.; Khan, F.; Kumar, P.; Pullar, T.; Belch, J. J. C-reactive protein: The underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47, 1780-1784.
44. Sodergren, A.; Karp, K.; Boman, K.; Eriksson, C.; Lundstrom, E.; Smedby, T.; Soderlund, L.; Rantapaa-Dahlqvist, S.; Wallberg-Jonsson, S. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res. Ther. 2010, 12, R158.
45. Foster, W.; Lip, G. Y.; Raza, K.; Carruthers, D.; Blann, A. D. An observational study of endothelial function in early arthritis. Eur. J. Clin. Investig. 2012, 42, 510-516.
46. Sandoo, A.; Veldhuijzen van Zanten, J. J.; Metsios, G. S.; Carroll, D.; Kitas, G. D. Vascular function and morphology in rheumatoid arthritis: A systematic review. Rheumatology (Oxford) 2011, 50, 2125-2139.
47. Littler, A. J.; Buckley, C. D.; Wordsworth, P.; Collins, I.; Martinson, J.; Simmons, D. L. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br. J. Rheumatol. 1997, 36, 164-169.
48. Klimiuk, P. A.; Fiedorczyk, M.; Sierakowski, S.; Chwiecko, J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand. J. Rheumatol. 2007, 36, 345-350.
49. Dessein, P. H.; Joffe, B. I.; Singh, S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res. Ther. 2005, 7, R634-R643.
50. Veale, D. J.; Maple, C.; Kirk, G.; McLaren, M.; Belch, J. J. Soluble cell adhesion molecules-P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand. J. Rheumatol. 1998, 27, 296-299.
51. Meyer, M. F.; Schmidt, O.; Hellmich, B.; Schatz, H.; Klein, H. H.; Braun, J. Microvascular dysfunction in rheumatoid arthritis assessed by laser Doppler anemometry: Relationship to soluble adhesion molecules and extraarticular manifestations. Rheumatol. Int. 2007, 28, 145-152.
52. Antoniades, C.; Demosthenous, M.; Tousoulis, D.; Antonopoulos, A. S.; Vlachopoulos, C.; Toutouza, M.; Marinou, K.; Bakogiannis, C.; Mavragani, K.; Lazaros, G.; et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension 2011, 58, 93-98.
53. Lima, D. S.; Sato, E. I.; Lima, V. C.; Miranda, F., Jr.; Hatta, F. H. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J. Rheumatol. 2002, 29, 292-297.
54. Kiss, E.; Soltesz, P.; Der, H.; Kocsis, Z.; Tarr, T.; Bhattoa, H.; Shoenfeld, Y.; Szegedi, G. Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J. Autoimmun. 2006, 27, 211-217.
55. El-Magadmi, M.; Bodill, H.; Ahmad, Y.; Durrington, P. N.; Mackness, M.; Walker, M.; Bernstein, R. M.; Bruce, I. N. Systemic lupus erythematosus: An independent risk factor for endothelial dysfunction in women. Circulation 2004, 110, 399-404.
56. Piper, M. K.; Raza, K.; Nuttall, S. L.; Stevens, R.; Toescu, V.; Heaton, S.; Gardner-Medwin, J.; Hiller, L.; Martin, U.; Townend, J.; et al. Impaired endothelial function in systemic lupus erythematosus. Lupus 2007, 16, 84-88.
57. Wright, S. A.; O'Prey, F. M.; Rea, D. J.; Plumb, R. D.; Gamble, A. J.; Leahey, W. J.; Devine, A. B.; McGivern, R. C.; Johnston, D. G.; Finch, M. B.; et al. Microcirculatory hemodynamics and endothelial dysfunction in systemic lupus erythematosus. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 2281-2287.
58. Svenungsson, E.; Cederholm, A.; Jensen-Urstad, K.; Fei, G. Z.; de Faire, U.; Frostegard, J. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Scand. J. Rheumatol. 2008, 37, 352-359.
59. Sfikakis, P. P.; Charalambopoulos, D.; Vayiopoulos, G.; Oglesby, R.; Sfikakis, P.; Tsokos, G. C. Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 1994, 12, 5-9.
60. Tulek, N.; Aydintug, O.; Ozoran, K.; Tutkak, H.; Duzgun, N.; Duman, M.; Tokgoz, G. Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with systemic lupus erythematosus. Clin. Rheumatol. 1996, 15, 47-50.
61. Machold, K. P.; Kiener, H. P.; Graninger, W.; Graninger, W. B. Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin. Immunol. Immunopathol. 1993, 68, 74-78.
62. Janssen, B. A.; Luqmani, R. A.; Gordon, C.; Hemingway, I. H.; Bacon, P. A.; Gearing, A. J.; Emery, P. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br. J. Rheumatol. 1994, 33, 1112-1116.
63. Spronk, P. E.; Bootsma, H.; Huitema, M. G.; Limburg, P. C.; Kallenberg, C. G. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin. Exp. Immunol. 1994, 97, 439-444.
64. Sari, R.; Taysi, S.; Erdem, F.; Yilmaz, Ö.; Keleş, S.; Kiziltunç, A.; Odabaş, A.; Çetinkaya, R. Correlation of serum levels of soluble intercellular adhesion molecule-1 with disease activity in systemic lupus erythematosus. Rheumatol. Int. 2001, 21, 149-152.
65. Sari, I.; Okan, T.; Akar, S.; Cece, H.; Altay, C.; Secil, M.; Birlik, M.; Onen, F.; Akkoc, N. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006, 45, 283-286.
66. Gonzalez-Juanatey, C.; Llorca, J.; Miranda-Filloy, J. A.; Amigo-Diaz, E.; Testa, A.; Garcia-Porrua, C.; Martin, J.; Gonzalez-Gay, M. A. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007, 57, 287-293.
67. Bodnar, N.; Kerekes, G.; Seres, I.; Paragh, G.; Kappelmayer, J.; Nemethne, Z. G.; Szegedi, G.; Shoenfeld, Y.; Sipka, S.; Soltesz, P.; et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J. Rheumatol. 2011, 38, 723-729.
68. Wendling, D.; Racadot, E.; Auge, B.; Toussirot, E. Soluble intercellular adhesion molecule 1 in spondylarthropathies. Clin. Rheumatol. 1998, 17, 202-204.
69. Sari, I.; Alacacioglu, A.; Kebapcilar, L.; Taylan, A.; Bilgir, O.; Yildiz, Y.; Yuksel, A.; Kozaci, D. L. Assessment of soluble cell adhesion molecules and soluble CD40 ligand levels in ankylosing spondylitis. Jt. Bone Spine 2010, 77, 85-87.
70. Kemeny-Beke, A.; Gesztelyi, R.; Bodnar, N.; Zsuga, J.; Kerekes, G.; Zsuga, M.; Biri, B.; Keki, S.; Szodoray, P.; Berta, A.; et al. Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters. Jt. Bone Spine 2011, 78, 184-187.
71. Erre, G. L.; Sanna, P.; Zinellu, A.; Ponchietti, A.; Fenu, P.; Sotgia, S.; Carru, C.; Ganau, A.; Passiu, G. Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: A cross-sectional study. Clin. Rheumatol. 2011, 30, 21-27.
72. Brezinski, E. A.; Follansbee, M. R.; Armstrong, E. J.; Armstrong, A. W. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: A systematic review. Curr. Pharm. Des. 2014, 20, 513-528.
73. Balci, D. D.; Balci, A.; Karazincir, S.; Ucar, E.; Iyigun, U.; Yalcin, F.; Seyfeli, E.; Inandi, T.; Egilmez, E. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J. Eur. Acad. Dermatol. Venereol. 2009, 23, 1-6.
74. Usta, M.; Yurdakul, S.; Aral, H.; Turan, E.; Oner, E.; Inal, B. B.; Oner, F. A.; Gurel, M. S.; Guvenen, G. Vascular endothelial function assessed by a noninvasive ultrasound method and serum asymmetric dimethylarginine concentrations in mild-to-moderate plaque-type psoriatic patients. Clin. Biochem. 2011, 44, 1080-1084.
75. Martyn-Simmons, C. L.; Ranawaka, R. R.; Chowienczyk, P.; Crook, M. A.; Marber, M. S.; Smith, C. H.; Barker, J. N. A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. Br. J. Dermatol. 2011, 164, 26-32.
76. Hatoum, O. A.; Binion, D. G.; Otterson, M. F.; Gutterman, D. D. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology 2003, 125, 58-69.
77. Kocaman, O.; Sahin, T.; Aygun, C.; Senturk, O.; Hulagu, S. Endothelial dysfunction in patients with ulcerative colitis. Inflamm. Bowel Dis. 2006, 12, 166-171.
78. Principi, M.; Mastrolonardo, M.; Scicchitano, P.; Gesualdo, M.; Sassara, M.; Guida, P.; Bucci, A.; Zito, A.; Caputo, P.; Albano, F.; et al. Endothelial function and cardiovascular risk in active inflammatory bowel diseases. J. Crohns Colitis 2013, 7, e427-e433.
79. Aloi, M.; Tromba, L.; di Nardo, G.; Dilillo, A.; del Giudice, E.; Marocchi, E.; Viola, F.; Civitelli, F.; Berni, A.; Cucchiara, S. Premature subclinical atherosclerosis in pediatric inflammatory bowel disease. J. Pediatr. 2012, 161, 589-594 e581.
80. Brand, D. D.; Latham, K. A.; Rosloniec, E. F. Collagen-induced arthritis. Nat. Protoc. 2007, 2, 1269-1275.
81. He, M.; Liang, X.; He, L.; Wen, W.; Zhao, S.; Wen, L.; Liu, Y.; Shyy, J. Y.; Yuan, Z. Endothelial dysfunction in rheumatoid arthritis: The role of monocyte chemotactic protein-1-induced protein. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1384-1391.
82. Denys, A.; Clavel, G.; Semerano, L.; Lemeiter, D.; Boissier, M. C. A1. 6 Vascular adhesion molecule VCAM-1 overexpression in collagen induced arthritis: A model for rheumatoid arthritis vascular dysfunction. Ann. Rheum. Dis. 2014, 73, A3.
83. Haruna, Y.; Morita, Y.; Komai, N.; Yada, T.; Sakuta, T.; Tomita, N.; Fox, D. A.; Kashihara, N. Endothelial dysfunction in rat adjuvant-induced arthritis: Vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase. Arthritis Rheum. 2006, 54, 1847-1855.
84. Fang, Z. Y.; Fontaine, J.; Unger, P.; Berkenboom, G. Alterations of the endothelial function of isolated aortae in rats with adjuvant arthritis. Arch. Int. Pharmacodyn. Ther. 1991, 311, 122-130.
85. Dooley, L. M.; Washington, E. A.; Abdalmula, A.; Tudor, E. M.; Kimpton, W. G.; Bailey, S. R. Endothelial dysfunction in an ovine model of collagen-induced arthritis. J. Vasc. Res. 2014, 51, 90-101.
86. Neumann, P.; Gertzberg, N.; Johnson, A. TNF-alpha induces a decrease in eNOS promoter activity. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286, L452-L459.
87. Kleinbongard, P.; Heusch, G.; Schulz, R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol. Ther. 2010, 127, 295-314.
88. Rajan, S.; Ye, J.; Bai, S.; Huang, F.; Guo, Y. L. NF-kappaB, but not p38 MAP kinase, is required for TNF-alpha-induced expression of cell adhesion molecules in endothelial cells. J. Cell. Biochem. 2008, 105, 477-486.
89. Bergh, N.; Ulfhammer, E.; Glise, K.; Jern, S.; Karlsson, L. Influence of TNF-alpha and biomechanical stress on endothelial anti-and prothrombotic genes. Biochem. Biophys. Res. Commun. 2009, 385, 314-318.
90. Wang, P.; Ba, Z. F.; Chaudry, I. H. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am. J. Physiol. 1994, 266, H2535-H2541.
91. Chia, S.; Qadan, M.; Newton, R.; Ludlam, C. A.; Fox, K. A.; Newby, D. E. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 695-701.
92. Hingorani, A. D.; Cross, J.; Kharbanda, R. K.; Mullen, M. J.; Bhagat, K.; Taylor, M.; Donald, A. E.; Palacios, M.; Griffin, G. E.; Deanfield, J. E.; et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000, 102, 994-999.
93. Ohta, H.; Wada, H.; Niwa, T.; Kirii, H.; Iwamoto, N.; Fujii, H.; Saito, K.; Sekikawa, K.; Seishima, M. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005, 180, 11-17.
94. Kundu, S.; Ghosh, P.; Datta, S.; Ghosh, A.; Chattopadhyay, S.; Chatterjee, M. Oxidative stress as a potential biomarker for determining disease activity in patients with rheumatoid arthritis. Free Radic. Res. 2012, 46, 1482-1489.
95. Picchi, A.; Gao, X.; Belmadani, S.; Potter, B. J.; Focardi, M.; Chilian, W. M.; Zhang, C. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ. Res. 2006, 99, 69-77.
96. Kalinowski, L.; Malinski, T. Endothelial NADH/NADPH-dependent enzymatic sources of superoxide production: Relationship to endothelial dysfunction. Acta Biochim. Pol. 2004, 51, 459-469.
97. Gielis, J. F.; Lin, J. Y.; Wingler, K.; van Schil, P. E.; Schmidt, H. H.; Moens, A. L. Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders. Free Radic. Biol. Med. 2011, 50, 765-776.
98. Hamilton, C. A.; Miller, W. H.; Al-Benna, S.; Brosnan, M. J.; Drummond, R. D.; McBride, M. W.; Dominiczak, A. F. Strategies to reduce oxidative stress in cardiovascular disease. Clin. Sci. (Lond.) 2004, 106, 219-234.
99. Wolin, M. S. Interactions of oxidants with vascular signaling Systems. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1430-1442.
100. Biniecka, M.; Kennedy, A.; Ng, C. T.; Chang, T. C.; Balogh, E.; Fox, E.; Veale, D. J.; Fearon, U.; O'Sullivan, J. N. Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis. Arthritis Res. Ther. 2011, 13, R121.
101. Ku, I. A.; Imboden, J. B.; Hsue, P. Y.; Ganz, P. Rheumatoid arthritis: Model of systemic inflammation driving atherosclerosis. Circ. J. 2009, 73, 977-985.
102. Hurt-Camejo, E.; Paredes, S.; Masana, L.; Camejo, G.; Sartipy, P.; Rosengren, B.; Pedreno, J.; Vallve, J. C.; Benito, P.; Wiklund, O. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: Possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum. 2001, 44, 2761-2767.
103. Norata, G. D.; Tonti, L.; Roma, P.; Catapano, A. L. Apoptosis and proliferation of endothelial cells in early atherosclerotic lesions: possible role of oxidised LDL. Nutr. Metab. Cardiovasc. Dis. 2002, 12, 297-305.
104. Vladimirova-Kitova, L.; Deneva, T.; Angelova, E.; Nikolov, F.; Marinov, B.; Mateva, N. Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. Clin. Physiol. Funct. Imaging 2008, 28, 417-425.
105. Stancu, C. S.; Toma, L.; Sima, A. V. Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis. Cell. Tissue Res. 2012, 349, 433-446.
106. Narshi, C. B.; Giles, I. P.; Rahman, A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus 2011, 20, 5-13.
107. Cieslik, P.; Hrycek, A.; Klucinski, P. Vasculopathy and vasculitis in systemic lupus erythematosus. Pol. Arch. Med. Wewn. 2008, 118, 57-63.
108. Gomez-Zumaquero, J. M.; Tinahones, F. J.; de Ramon, E.; Camps, M.; Garrido, L.; Soriguer, F. J. Association of biological markers of activity of systemic lupus erythematosus with levels of anti-oxidized low-density lipoprotein antibodies. Rheumatology (Oxford) 2004, 43, 510-513.
109. Charakida, M.; Besler, C.; Batuca, J. R.; Sangle, S.; Marques, S.; Sousa, M.; Wang, G.; Tousoulis, D.; Delgado Alves, J.; Loukogeorgakis, S. P.; et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009, 302, 1210-1217.
110. Hjeltnes, G.; Hollan, I.; Forre, O.; Wiik, A.; Lyberg, T.; Mikkelsen, K.; Agewall, S. Endothelial function improves within 6 weeks of treatment with methotrexate or methotrexate in combination with a TNF-alpha inhibitor in rheumatoid arthritis patients. Scand. J. Rheumatol. 2012, 41, 240-242.
111. Cardillo, C.; Schinzari, F.; Mores, N.; Mettimano, M.; Melina, D.; Zoli, A.; Ferraccioli, G. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin. Pharmacol. Ther. 2006, 80, 275-281.
112. Bilsborough, W.; Keen, H.; Taylor, A.; O'Driscoll, G. J.; Arnolda, L.; Green, D. J. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol. Int. 2006, 26, 1125-1131.
113. Hurlimann, D. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106, 2184-2187.
114. Gonzalez-Juanatey, C.; Testa, A.; Garcia-Castelo, A.; Garcia-Porrua, C.; Llorca, J.; Gonzalez-Gay, M. A. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum. 2004, 51, 447-450.
115. Sidiropoulos, P. I.; Siakka, P.; Pagonidis, K.; Raptopoulou, A.; Kritikos, H.; Tsetis, D.; Boumpas, D. T. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand. J. Rheumatol. 2009, 38, 6-10.
116. Bosello, S.; Santoliquido, A.; Zoli, A.; di Campli, C.; Flore, R.; Tondi, P.; Ferraccioli, G. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin. Rheumatol. 2008, 27, 833-839.
117. Komai, N.; Morita, Y.; Sakuta, T.; Kuwabara, A.; Kashihara, N. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod. Rheumatol. 2007, 17, 385-390.
118. Van Eijk, I. C.; Peters, M. J.; Serne, E. H.; van der Horst-Bruinsma, I. E.; Dijkmans, B. A.; Smulders, Y. M.; Nurmohamed, M. T. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann. Rheum. Dis. 2009, 68, 362-366.
119. Syngle, A.; Vohra, K.; Sharma, A.; Kaur, L. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin. Rheumatol. 2010, 29, 763-770.
120. Avgerinou, G.; Tousoulis, D.; Siasos, G.; Oikonomou, E.; Maniatis, K.; Papageorgiou, N.; Paraskevopoulos, T.; Miliou, A.; Koumaki, D.; Latsios, G.; et al. Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int. J. Cardiol. 2011, 151, 382-383.
121. Schinzari, F.; Armuzzi, A.; de Pascalis, B.; Mores, N.; Tesauro, M.; Melina, D.; Cardillo, C. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease. Clin. Pharmacol. Ther. 2008, 83, 70-76.
122. Galarraga, B.; Belch, J. J.; Pullar, T.; Ogston, S.; Khan, F. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy. J. Rheumatol. 2010, 37, 521-528.
123. Kerekes, G.; Soltesz, P.; Der, H.; Veres, K.; Szabo, Z.; Vegvari, A.; Szegedi, G.; Shoenfeld, Y.; Szekanecz, Z. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin. Rheumatol. 2009, 28, 705-710.
124. Veselinovic, M. V.; Zivkovic, V. I.; Toncev, S.; Tasic, N.; Bogdanovic, V.; Djuric, D. M.; Jakovljevic, V. Carotid artery intima-media thickness and brachial artery flow-mediated vasodilatation in patients with rheumatoid arthritis. VASA 2012, 41, 343-351.
125. Hafstrom, I.; Rohani, M.; Deneberg, S.; Wornert, M.; Jogestrand, T.; Frostegard, J. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. J. Rheumatol. 2007, 34, 1810-1816.
126. Maki-Petaja, K. M.; Booth, A. D.; Hall, F. C.; Wallace, S. M.; Brown, J.; McEniery, C. M.; Wilkinson, I. B. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J. Am. Coll. Cardiol. 2007, 50, 852-858.
127. Tikiz, C.; Utuk, O.; Pirildar, T.; Bayturan, O.; Bayindir, P.; Taneli, F.; Tikiz, H.; Tuzun, C. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J. Rheumatol. 2005, 32, 2095-2101.
128. Hermann, F.; Forster, A.; Chenevard, R.; Enseleit, F.; Hurlimann, D.; Corti, R.; Spieker, L. E.; Frey, D.; Hermann, M.; Riesen, W.; et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J. Am. Coll. Cardiol. 2005, 45, 461-464.
129. Ferreira, G. A.; Navarro, T. P.; Telles, R. W.; Andrade, L. E.; Sato, E. I. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: An 8 weeks controlled trial. Rheumatology (Oxford) 2007, 46, 1560-1565.
130. Klimiuk, P. A.; Sierakowski, S.; Domyslawska, I.; Chwiecko, J. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis. Scand. J. Rheumatol. 2009, 38, 439-444.
131. Gonzalez-Gay, M. A.; Garcia-Unzueta, M. T.; de Matias, J. M.; Gonzalez-Juanatey, C.; Garcia-Porrua, C.; Sanchez-Andrade, A.; Martin, J.; Llorca, J. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2006, 24, 373-379.
132. Ruyssen-Witrand, A.; Fautrel, B.; Saraux, A.; Le Loet, X.; Pham, T. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review. Jt. Bone Spine 2011, 78, 23-30.
133. Roman, M. J.; Shanker, B. A.; Davis, A.; Lockshin, M. D.; Sammaritano, L.; Simantov, R.; Crow, M. K.; Schwartz, J. E.; Paget, S. A.; Devereux, R. B.; et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 2003, 349, 2399-2406.
134. Palinski, W. Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1745-1750.
135. Kanda, H.; Hamasaki, K.; Kubo, K.; Tateishi, S.; Yonezumi, A.; Kanda, Y.; Yamamoto, K.; Mimura, T. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J. Rheumatol. 2002, 29, 2024-2026.
136. McCarey, D. W.; McInnes, I. B.; Madhok, R.; Hampson, R.; Scherbakova, O.; Ford, I.; Capell, H. A.; Sattar, N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): Double-blind, randomised placebo-controlled trial. Lancet 2004, 363, 2015-2021.
137. Okamoto, H.; Koizumi, K.; Kamitsuji, S.; Inoue, E.; Hara, M.; Tomatsu, T.; Kamatani, N.; Yamanaka, H. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J. Rheumatol. 2007, 34, 964-968.
138. Sheng, X.; Murphy, M. J.; Macdonald, T. M.; Wei, L. Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J. Rheumatol. 2012, 39, 32-40.
139. Semb, A. G.; Kvien, T. K.; DeMicco, D. A.; Fayyad, R.; Wun, C. C.; LaRosa, J. C.; Betteridge, J.; Pedersen, T. R.; Holme, I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012, 64, 2836-2846.